论文部分内容阅读
目的 探讨非小细胞肺癌 (NSCLC)中第 3号染色体短臂 ( 3p)上两个独特区域——— 3p14和3p2 5等位基因的杂合性丢失 (LOH)与NSCLC发生、发展之间的关系。方法 采用聚合酶链反应 (PCR)结合二核苷酸 (CA)n重复序列多态性方法 ,分析 162例新鲜NSCLC手术标本、85例癌旁肺组织及 5例肺部良性疾病组织中 3p14和 3p2 5位点的LOH。结果 162例NSCLC组织中共有 10 8例 ( 66.67% )出现LOH ,84例 ( 5 1.85 % )为 3p2 5LOH ,65例 ( 4 0 .12 % )为 3p14LOH ,其中 41例 ( 2 5 .3 1% )同时出现 3p14和 3p2 5两个位点的丢失。 3pLOH与肺癌组织学分类及TNM分期均无明显关系。但腺癌中 3 8% ( 19/5 0 )同时出现3p2 5和 3p14LOH ,明显高于鳞癌 ( 19.5 1% ,16/82 ) (P <0 .0 5 )。而且发生 3p14LOH的Ⅱ期NSCLC患者( 5 1.2 8% ,2 0 /3 9)和Ⅲ期患者 ( 4 4.93 % ,3 1/69)均明显高于Ⅰ期 ( 2 5 .93 % ,14 /5 4) (P均 <0 .0 5 )。 85例癌旁肺组织及 5例肺部良性疾病组织均未发现 3pLOH。结论 3p杂合性丢失普遍存在于NSCLC中。在这些丢失区域内可能存在一个或多个抑癌基因 ,与肺癌的发生发展有关
Objective To investigate the association between loss of heterozygosity (LOH) of 3p14 and 3p2 5 alleles and occurrence and development of NSCLC in two distinct regions of short arm (3p) of chromosome 3 in non-small cell lung cancer (NSCLC) relationship. Methods The polymerase chain reaction (PCR) and dinucleotide (CA) n repeat polymorphism were used to analyze 162 cases of fresh NSCLC specimens, 85 cases of paracancerous lung tissues and 5 cases of benign lung diseases, 3p14 and 3p2 5-site LOH. Results A total of 108 patients (66.67%) had LOH in 84 cases (5 1.85%), 3p2 5LOH in 65 cases (4.12%) and 3p14LOH in 41 cases (25.31% ) Both the 3p14 and 3p2 5 sites were lost at the same time. 3pLOH and lung cancer histological classification and TNM staging no significant relationship. However, 38% (19/5 0) of adenocarcinomas showed both 3p2 5 and 3p14LOH, which was significantly higher than that of squamous cell carcinoma (19.5%, 16/82) (P <0.05). Moreover, stage Ⅱ NSCLC patients with 3p14LOH (5 1.2 8%, 20/30) and stage Ⅲ patients (4.93%, 3 1/69) were significantly higher than those in stage Ⅰ (25.93%, 14/5 4) (P <0.05). No 3pLOH was found in 85 cases of paracancerous lung tissues and 5 cases of benign lung diseases. Conclusion Loss of 3p heterozygosity is common in NSCLC. There may be one or more tumor suppressor genes in these lost regions, which are related to the occurrence and development of lung cancer